{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:05:34Z","timestamp":1790827534968,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T00:00:00Z","timestamp":1690070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2017TYTWZ3_002"],"award-info":[{"award-number":["2017TYTWZ3_002"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004271","name":"Sapienza Universit\u00e0 di Roma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020555","name":"Ospedale Pediatrico Bambino Ges\u00f9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003197","name":"AIFA","doi-asserted-by":"publisher","award":["TRS-2018-00001336"],"award-info":[{"award-number":["TRS-2018-00001336"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jcv.2023.105551","type":"journal-article","created":{"date-parts":[[2023,7,23]],"date-time":"2023-07-23T13:30:02Z","timestamp":1690119002000},"page":"105551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals"],"prefix":"10.1016","volume":"168","author":[{"given":"D.","family":"Armenia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Alteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Svicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Cento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vergori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cicalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Forbici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fabeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Brugneti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Gennari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Malagnino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Andreoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.F.","family":"Perno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ceccherini-Silberstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2023.105551_bib0001","series-title":"HIV Antiretroviral Therapy","author":"Kemnic","year":"2021"},{"key":"10.1016\/j.jcv.2023.105551_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/2325958219867325","article-title":"Optimizing antiretroviral therapy in treatment-experienced patients living with HIV: a critical review of switch and simplification strategies. An opinion of the HIV practice and research network of the American college of clinical pharmacy","volume":"18","author":"Chastain","year":"2019","journal-title":"J. Int. Assoc. Provid AIDS Care"},{"key":"10.1016\/j.jcv.2023.105551_bib0003","series-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV","year":"2023"},{"key":"10.1016\/j.jcv.2023.105551_bib0004","unstructured":"European AIDS Clinical Society. Guidelines - version 11.1 2022. https:\/\/www.eacsociety.org\/media\/guidelines-11.1_final_09-10.pdf."},{"key":"10.1016\/j.jcv.2023.105551_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00052-22","article-title":"Genotypic resistance testing of HIV-1 DNA in peripheral blood mononuclear cells","author":"Chu","year":"2022","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jcv.2023.105551_bib0006","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s40121-022-00676-y","article-title":"HIV DNA sequencing to detect archived antiretroviral drug resistance","volume":"11","author":"Geretti","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.jcv.2023.105551_bib0007","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jac\/dkq544","article-title":"Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia","volume":"66","author":"Wirden","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2023.105551_bib0008","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1468-1293.2012.01002.x","article-title":"Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication","volume":"13","author":"Delaugerre","year":"2012","journal-title":"HIV Med."},{"key":"10.1016\/j.jcv.2023.105551_bib0009","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1093\/jac\/dky315","article-title":"Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia","volume":"73","author":"Rodriguez","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2023.105551_bib0010","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature01709","article-title":"Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts","volume":"424","author":"Mangeat","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jcv.2023.105551_bib0011","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1371\/journal.pgen.1002550","article-title":"APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete \u201call or nothing\u201d phenomenon","volume":"8","author":"Armitage","year":"2012","journal-title":"PLos Genet."},{"key":"10.1016\/j.jcv.2023.105551_bib0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1742-4690-6-16","article-title":"APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA","volume":"6","author":"Russell","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.jcv.2023.105551_bib0013","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1128\/JCM.00893-15","article-title":"Genotypic tropism testing in HIV-1 proviral DNA can provide useful information at low-level viremia","volume":"53","author":"Fabeni","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2023.105551_bib0014","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jcv.2016.07.007","article-title":"Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA","volume":"82","author":"Zaccarelli","year":"2016","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2023.105551_bib0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcv.2018.04.001","article-title":"Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment","volume":"104","author":"Armenia","year":"2018","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2023.105551_bib0016","first-page":"1","article-title":"Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate combination","author":"Lambert-Niclot","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2023.105551_bib0017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/15284336.2015.1115585","article-title":"Clinical outcomes of virologically-suppressed patients with pre-existing HIV-1 drug resistance mutations switching to rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate in the SPIRIT study","volume":"17","author":"Porter","year":"2016","journal-title":"HIV Clin. Trials"},{"key":"10.1016\/j.jcv.2023.105551_bib0018","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1093\/jac\/dkab123","article-title":"Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoir","volume":"76","author":"Abdi","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2023.105551_bib0019","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/jac\/dkaa002","article-title":"Characterization of drug resistance and the defective HIV reservoir in virally suppressed vertically infected children in Mali","volume":"75","author":"Brice","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2023.105551_bib0020","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/jmv.25474","article-title":"Routine drug resistance testing in proviral HIV-1 DNA: Prevalence of stop codons and hypermutation, and associated factors","volume":"91","author":"Alidjinou","year":"2019","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jcv.2023.105551_bib0021","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jviromet.2017.10.016","article-title":"Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy","volume":"251","author":"Allavena","year":"2018","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.jcv.2023.105551_bib0022","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cmi.2015.10.004","article-title":"Contribution of APOBEC3G\/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants","volume":"22","author":"Noguera-Julian","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jcv.2023.105551_bib0023","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1097\/QAD.0b013e3283560703","article-title":"E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure","volume":"26","author":"Fourati","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2023.105551_bib0024","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/QAD.0000000000000182","article-title":"Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments","volume":"28","author":"Fourati","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2023.105551_bib0025","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/jac\/dkz554","article-title":"HIV MDR is still a relevant issue despite its dramatic drop over the years","author":"Armenia","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2023.105551_bib0026","article-title":"Prevalence and factors associated with HIV-1 multidrug resistance over the past two decades in the Italian Arca database","author":"Lombardi","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jcv.2023.105551_bib0027","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/hiv.12411","article-title":"Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe","volume":"18","author":"Judd","year":"2017","journal-title":"HIV Med."},{"key":"10.1016\/j.jcv.2023.105551_bib0028","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.cmi.2019.07.004","article-title":"Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients","volume":"25","author":"Ungaro","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jcv.2023.105551_bib0029","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/jac\/dkaa072","article-title":"Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study","volume":"75","author":"Navarro","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jcv.2023.105551_bib0030","unstructured":"Andreatta K., Willkom M., Martin R., Chang S., Wei L., Liu H., et\u00a0al. Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with antiretroviral resistance including M184V\/I 2023 10.1093\/jac\/dkz347."},{"key":"10.1016\/j.jcv.2023.105551_bib0031","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jcv.2018.06.012","article-title":"Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA)","volume":"105","author":"Rusconi","year":"2018","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2023.105551_bib0032","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/QAD.0000000000002850","article-title":"Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation","volume":"35","author":"Li","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.jcv.2023.105551_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106492","article-title":"Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV","volume":"59","author":"Armenia","year":"2022","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653223001749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653223001749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:07:03Z","timestamp":1778612823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653223001749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":33,"alternative-id":["S1386653223001749"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2023.105551","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2023.105551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105551"}}